BCL2L1 and colorectal cancer: Moreover, compared with a Bcl-2-selective inhibitor, NP-encapsulated ABT-737 is likely to be more effective against tumors such as colorectal cancer that frequently overexpress Bcl-X(L),37,38 the expression of which was uniformly high in the three colorectal cancer models assessed.